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ABSTRACT 
Objective: In this study an improved RP-HPLC method was developed for the simultaneous estimation of Aspirin, Atrovastatin, and Clopidogrel in 
pharmaceutical dosage form. For improving the separation, an experimental design approach was employed. 
Methods: Factors–independent variables (Organic modifier, pH of the mobile phase and flow rate) were extracted from the preliminary study and 
as dependent three responses variables viz. Capacity factor of tR1, resolution between Atorvastatin and internal standard, retention time of tR4
Results: The procedure allowed deduction of optimal conditions and the predicted optimum was Acetonitrile: Methanol: 0.1% of Triethylamine 
(52:05:43, v/v/v), pH of the aqueous phase adjusted at to 3.0 with 10 % ortho phosphoric acid, and the separation was achieved within 8 minutes. 
The method showed good agreement between the experimental data and predictive value throughout the studied parameter space.  
 
were selected. To improve method development and optimization, Derringer’s desirability function was applied to simultaneously optimize the 
chosen three responses.  
Conclusion: The optimized assay condition was validated according to International Conference on Harmonisation (ICH) guidelines to confirm 
specificity, linearity, accuracy and precision. The proposed validated method was successfully applied for the analysis of commercially available 
dosage form. 
Keywords: Central composite design, Multiple response optimizations, HPLC method, Aspirin, Atrovastatin, and Clopidogrel. 
 
INTRODUCTION 
Aspirin (ASP) is chemically known as 2-(acetyloxy)-benzoic acid, 
small doses of aspirin inhibit the synthesis of TXA2 by platelets but 
higher doses also inhibit prostacyclin formation in the vessel walls 
as well [1]. Atrovastatin (ATV) is chemically known as [R-(R, R)]-2-
(4-fluorophenyl)-5,5 ,-dihydroxy-5-(1-methylethyl)–3-phenyl4 
[(phenylamino) carbonyl] -lH-pyrrole-1-heptanoic acid a potent 
inhibitor of the enzyme hydroxymethylglutaryl co-enzyme A-
reductase (HMG-COA reductase, the rate limiting enzyme in 
cholesterol synthesis in the liver [2]. Clopidogrel bisulfate (CLP), is 
chemically (+)-(S)-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c] 
pyridine- 5 (4H) acetic acid methyl ester sulphate is a potent oral 
antiplatelet agent often used in the treatment of coronary artery 
disease, peripheral vascular disease and cerebro vascular disease. 
The major risk factors for a fatal cardiovascular disease are high 
blood cholesterol, high blood pressure, smoking, diabetes, poor diet 
and overweight. The common cardiovascular diseases are aneurysm, 
angina, atherosclerosis, cerebrovascular accident (stroke), 
cerebrovascular disease, congestive heart failure, coronary artery 
disease, myocardial infarction (heart attack) and peripheral vascular 
diseases Usage of fixed dose combinations in cardiovascular 
diseases have many advantages such as reduction in cost, adverse 
effects and dose, ease of use by patients, improved patient 
compliance and medication adherence. 
The review of literature revealed that various analytical methods 
involving RP-HPLC, Spectrophotometry have been reported for ASP 
[3], ATV [4] and CLP [5] in single form and in combination with 
other drugs. The simultaneous determination of CLP and ASP in 
combined oral dosage forms was also reported [6]. However, 
recently a simultaneous estimation of all the three drugs in a single 
combination dosage form with the aid of chemometric assisted UV 
spectroscopic and liquid chromatographic method, has been 
described by [7]. The reported analytical method mostly focused on 
UV- spectrophotometry (H-Point addition) method. It has a limited 
focus on HPLC method development and does not provide details on 
separation attributes like capacity factor, resolution, and 
asymmetric factor. 
It is noticed that none of the above methods applied a systematic 
optimization procedure for the simultaneous HPLC estimation of 
ASP, ATV, and CLP, but employed a time-consuming trial-and error 
approach resulting only in an apparent optimum and information 
concerning the sensitivity of the factors on the analytes separation 
and interaction between factors is not available. In this work 
chemometric procedure is applied to realize the above 
objective.However, HPLC method intended to be applied for the 
pharmaceutical or industrial environment, there is a need to 
optimize multiple responses (analysis time and resolution) 
simultaneously [8, 9]. To achieve global optimization of multiple 
responses the Derringer's desirability function (Multi-Criteria 
decision making) has been applied [10]. Hence there was a need to 
develop an improved HPLC method, for simultaneous estimation of 
ASP, ATV, and CLP in pharmaceutical formulations, with aid of 
chemometric protocol. 
The aim of this work is to (i) develop an improved HPLC method for 
the simultaneous analysis of ASP, ATV, and CLP in pharmaceutical 
dosage form and (ii) provide information on the sensitivity of 
chromatographic factors and their interaction effects on the 
separation characteristics.  
Experimental 
Apparatus 
In this study was performed with a Shimadzu (Japan) 
chromatograph equipped with an LC-20 AD and LC-20 AD vp 
solvent-delivery module, an SPD-20A PDA detector, and a Rheodyne 
model 7125 injector valve fitted with a 20 µL sample loop. The 
system was controlled through a system controller (SCL-10A) and a 
personal computer using a Shimadzu chromatographic software (LC 
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degassed using Branson sonicator (Branson Ultrasonics 
Corporation, USA). Absorbance spectra were recorded using an UV-
Visible spectrophotometer (Model UV-1601PC, Japan) employing 
quartz cell of 1.00 cm of path length. The chromatographic analyses 
were done on an phenomenex analytical column Gemini C18 (150 
mm × 4.6 mm I. D and 5 µm particle size). 
MATERIALS AND METHODS 
Working standards of aspirin, atrovastatin, and clopidogrel were 
gifts from RanbaxyLaboratery Ltd., New Delhi, India. Warfarin 
(Internal Standard) was gifts from Sasun Lab. Ltd., Pondy. The 
marketed formulation was purchased from whole saler (Ecosprin® 
Gold 20). Acetonitrile (MeCN) and Methanol (MeOH) of HPLC grade 
and Triethylamine (TEA) and other reagents of analytical-reagent 
grade were from SD Fine Chemicals (Mumbai, India). The HPLC-
grade water was prepared by using Milli-Q Academic, Millipore, 
Bangalore, India. 
Software 
Experimental design, data analysis and desirability function 
calculations were performed by using Design-Expert 8.0.0 (Stat-Ease 
Inc., Minneapolis) and individual desirability function was 
performed by JMP-Software 9.0.0 (SAS) trail version. 
Standard solutions 
Standard stock solutions of ASP, ATV and CLP (1mg/ml) were 
prepared in the mobile phase. Working standard solutions were 
freshly obtained by diluting the standard stock solutions with 
mobile phase during the analysis time. Calibration curves reporting 
peak area ratios of ASP, ATV and CLP to that of the IS versus drug 
concentrations were established in the range of 2-10 µg/mL for ASP, 
CLP, and 1-5 µg/mL for ATV, in presence of warfarin (5µg/mL) as 
internal standard. Standard solution prepared for the optimization 
procedure constituted 4 µg/mL of ASP, CLP, and ATV for 2 µg/mL, 
respectively. 
Sample preparation 
Twenty capsules were weighed and mixed thoroughly, an amount of 
capsule powdered equivalent to 40mg for ASP, CLP, and 10mg of 
ATV were accurately weighed and transferred in a 100 ml 
Volumetric flask: suitable quantity of IS was added followed by 75 
ml of mobile phase. The mixture was subjected to sonication for 15 
min then complete extraction of drugs and the solution was made up 
to the mark with the mobile phase to obtain a concentration of ASP, 
CLP, 4 µg/mL and ATV for 2 µg/mL, respectively. The solution was 
centrifuged at 2500 rpm for 10 min; the clear supernatant was 
collected and filtered through a 0.45 µm membrane filter (pall tech, 
India) and 20 µl of this solution was injected for HPLC analysis. 
Validation study 
In accordance with the ICH guidelines on the validation of analytical 
methods Q2A and Q2B, the following validation characteristics were 
examined: specificity, linearity, Accuracy, precision, Limit of Detection 
(LOD) and Limit of Quantification (LOQ). For specificity study, placebo 
containing starch, lactose monohydrate, aerosil, hydroxy propyl 
methylcellulose, and titanium dioxide, magnesium stearate was used. 
There is no interference from the extracted blank, extraction solvent, and 
excipients used for the drug preparations on the retention times of the 3 
compounds of interest. Linearity was established at five levels over the 
concentration ranges of 2-10 µg/mL for Aspirin, Clopidogril, and 1-5 
µg/mL for Atrovastatine (approximately from 20 to 200% of nominal 
range of analyte) [11] with regression coefficient values more than 
0.999, which showed reproducibility. LOD and LOQ is 4.06 ng/ml, 12.32 
ng/ml of ASP, 1.37 ng/ml, 4.17 ng/ml of CLP, and 7.85 ng/ml, 23.78 
ng/ml of ATV was founded respectively. 
Chromatographic procedure 
Chromatographic separations were carried out on a Phenomenex® 
C18 analytical column (150 mm × 4.6 mm i. d., 5 µm) connected with 
a Phenomenex® C18 guard cadridge (4 mm × 3 mm i. d., 5 µm). The 
mobile phase consisted of Acetonitrile: Methanol: 0.1% 
Triethylamine, pH of mobile phase adjusted to 3.0 with 10% ortho 
phosphoric acid. In order to increase the sensitivity for the less 
concentrated compound and to decrease the background from 
mobile phase a wavelength of 220 nm was selected for detection. An 
injection volume of the sample was 20 µl. The HPLC system was 
used in an air-conditioned laboratory atmosphere (20 ± 2°C). 
RESULTS AND DISCUSSION 
Optimization design and analysis 
The central composite design was applied to optimize the separation 
and to assist the development of better understanding of the 
interaction of several chromatographic factors on separation quality 
[12]. In this work, the important chromatographic factors were 
selected and optimized by a central composite design experiment. 
The selection of factors for optimization was based on preliminary 
experiments and prior knowledge from literature, as well as certain 
instrumental limitations. From preliminary experiments, the key 
factors selected for optimization processes were MeCN 
concentration (A), pH of the mobile phase (B) and flow rate (C). 
table 1 shows the levels of each factors studied for finding out the 
optimum values and responses. As can be seen in this table, the 
ranges of each factors used were: MeCN concentration (45-55%), pH 
(3.0-4.0) and flow rate (1.0-1.4 ml/min). As response variables, the 
capacity factor (k) of (tR1) and retention time of CLP (tR4), then 
resolution of ATV-IS (Rs2,3
 
Where Y is the response to be modeled, β is the regression 
coefficient and X
) was chosen. All experiments were 
performed in randomized order to minimize the effects of 
uncontrolled variables that may introduce a bias on the 
measurements. Replicates (n=6) of the central points were 
performed to estimate the experimental error. For an experimental 
design with three factors, the model including linear, quadratic, and 
cross terms can be expressed as 
1, X2 and X3
Since R
 represent factors A, B and C 
respectively. To obtain a simple and yet a realistic model, the 
insignificant terms (P>0.05) are eliminated from the model through 
‘backward elimination’ process. The statistical parameters obtained 
from the ANOVA for the reduced models are given in table 2.  
2 always decreases when a regress or variable is eliminated 
from a regression model, in statistical modeling the adjusted R2 
which takes the number of regress or variables into account, is 
usually selected. In the present study, the adjusted R2 were well 
within the acceptable limits of R2≥0.80 which revealed that the 
experimental data shows a good fit with the second-order 
polynomial equations [13]. For all the reduced models, P value of 
<0.05 are obtained, implying these models are significant. The 
adequate precision value is a measure of the “signal (response) to 
noise (deviation) ratio”. A ratio greater than 4 is desirable [14]. In 
this study, the ratio was found to be in the range of 10.061 to 44.35, 
which indicates an adequate signal and therefore the model is 
significant for the separation process. The coefficient of variation 
(CV) is a measure of reproducibility of the model and as a general 
rule a model can be considered reasonably reproducible if it is less 
than 10%. The CV for all the models was found to less than 10%. As 
can be seen in table 2, the interaction term with the largest absolute 
coefficients among the fitted models is AB (+0.43) of tR4 model. The 
positive interaction between A and B is statistically significant 
(P=0.0001) for tR4.  The study reveals that changing the fraction of 
MeCN from low to high results in a rapid decline in tR4 both at the 
low and high level of flow rate. Especially this interaction is 
synergistic, as it led to a decrease in run time. The existence of such 
interactions emphasizes the necessity to carry out active multifactor 
experiments for optimization of the chromatographic separation 
[15]. In order to gain a better understanding of the results, the 
predicted models are presented in Fig. 1 as the perturbation plot. 
For an optimization design, this graph shows how the response 
changes as each factor moves from a chosen reference point, with all 
other factors held constant at the reference value. A steep slope or 
curvature in a factor indicates that the response is sensitive to that 
factor. Hence, the plot shows that factor A mostly affected the 
analysis time (tR4
2 2 2
0 1 1 2 2 3 3 12 1 2 13 1 3 23 2 3 11 1 22 2 33 3Y X X X X X X X X X X X X= β +β +β +β +β +β +β +β +β +β
) followed by factor B and then C. 
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50.00 1.20 3.50 1.01 15.76 3.69 
45.00 1.00 4.00 1.55 31.41 8.29 
55.00 1.40 4.00 0.64 10.08 2.21 
55.00 1.00 3.00 2.09 13.64 1.68 
55.00 1.40 3.00 0.62 07.47 1.59 
  a 
 
Randomized 
Table 2: Reduced response modelsa
 Response 
 and statistical parameters obtained from ANOVA  (After backward elimination) 
Regression model Model p-value %CV R-Square Adj.R-Square 
 K +0.90 +8.225E-003A- B-0.12 C+0.087BC <0.0001 4.95 0.9936        0.9798 
 tR4 +15.29-5.27A 2.82B+3.75C+0.43AB-2.75AC +1.15A2 <0.0001 7.26 0.9832 0.9681 
Rs +3.58-2.67A-0.21B+0.44C 2,3 <0.0001 6.76 0.9925 0.9857 
              a 
 
Only significant coefficients with P < 0.05 are included. Factors are in coded levels. 
Table 3: Criteria for the optimization of the individual responses 
Response Lower limit Upper limit Criteria 
Goal Importance 
k 0.5 1 2.0 Range 1 
 tR 7.5 4 13.0 Minimize 3 
Rs 1.5 2,3 2.5 Maximize 3 
 
Table 4: The comparison of experimental and predictive values of different objective functions under optimal conditions. 
Optimum Conditions  MeCN (%) pH    Flow  (ml/min) k1 tR   4 Rs    2,3 










Predictive    0.72                       7.23 2.60 
Experimental       
Error (%)    2.70 2.35 3.84 
                   
 
Fig. 1: Perturbation plot showing the effect of each of the 
independent variables on tR4 while keeping other variables at 
their respective midpoint levels 
 
Fig. 2: Graphical representation of the overall desirability 
function D. MECN concentration,  (A)is plotted against flow rate 
(B) with factor C held constant at pH 3.0 
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Fig. 3: Overlay chromatogram corresponding to (A) a placebo 
solution; (B) working standard of ASP (4µg/ml), ATV (2 µg/ml), 
IS (5 µg/ml) and CLP (4µg/ml); (C) a real sample of Ecosprin® 
Gold20 Capsules containing ASP (4µg/ml), ATV (2 µg/ml), IS (5 
µg/ml) and CLP (4µg/ml) 
 
Multi-criteria decision making 
In the present study, to optimize three responses with different 
targets, Derringer’s desirability function, was used. The Derringer’s 
desirability function, D, is defined as the geometric mean, weighted, 
or otherwise, of the individual desirability functions. The expression 
that defines the Derringer’s desirability function is:  
 
Where pi is the weight of the response, n the number of responses 
and di is the individual desirability function of each response 
obtained from the transformation of the individual response of each 
experiment. The scale of the individual desirability function ranges 
between d i  = 0, for a completely undesired response, to d i  = 1 for a 
fully desired response. Weights can range from 0.1 to 10. Weights 
lower than 1 give less emphasis to the goal, whereas weights greater 
than 1 give more emphasis to the goal in both cases [16], di varies in 
a non linear way while approaching the desired value. But with a 
weight of 1, d i
A value of D different to zero implies that all responses are in a 
desirable range simultaneously and consequently, for a value of D 
close to 1, the combination of the different criteria is globally 
optimal, so as the response values are near target values. The 
criteria for the optimization of each individual response are shown 
in table 3, and it is proposed for selecting an optimum experimental 
condition for analyzing routine quality control samples.  
 varies in a linear way. In the present report we chose 
weights equal to 1 for all the six responses.  
As can be seen under criteria (Table 3), were responses Rs2,3 
maximized, capacity factor in the range and tR4 minimized, were in 
order to shorten the analysis time. Importance can range from 1 (the 
least important) to 5 (the most important), which gives emphasis to 
a target value. For instance, high importance value of 3 was assigned 
to tR4
The predicted response values corresponding to the latter value of D 
were: k
 response as short analysis time is usually preferred for 
routine analysis. Following the conditions and restrictions above, 
the optimization procedure was carried out. The response surface 
obtained for the global desirability function is presented in Fig. 2. 
The coordinates producing the maximum desirability value (D= 
0.942) were MeCN concentration of 52.06%, pH of the mobile phase 
3.0 and flow rate of 1.4 ml/min. 
1 = 0.74, tR4 = 7.4 min Rs2, 3
Assay method validation 
 = 2.5. The prediction efficiency of 
the model was confirmed by performing the experiment under the 
optimal condition and the corresponding chromatogram is shown in 
Fig. 3. The agreement between experimental and predicted 
responses for the predicted optimum is shown in table 4. The errors 
for retention factor, retention time and resolution were 2.70, 2.35, 
and 3.84 %., respectively which were found to be in good agreement 
[17], with a difference of 1–6%. 
The optimised assay method is specific in relation to the placebo 
used in this study because there was no excipients peak co-eluted 
with the analytes and IS (Fig. 4). An excellent linearity was 
established at five levels in the range of 2-10 µg/mL for Aspirin, 
Clopidogril, and 1-5 µg/mL for Atrovastatin with R2
Application of the method 
 of more than 
0.999. The LOD and LOQ were estimated as 4.06 ng/ml, 12.32 ng/ml 
of ASP, 1.37 ng/ml, 4.17 ng/ml of CLP, and 7.85 ng/ml, 23.78 ng/ml 
of ATV. Accuracy (n=9), assessed by spike recovery, were found to 
be 99.86 for ASP, ATV and CLP was within acceptable ranges of 
100±2%. The intra and inter-assay precision (n=6) was confirmed 
since, the %C. V. Were well within the target criterion of ≤ 2. [18]. 
Robustness study reveals that small changes did not alter the 
retention times, retention factor and resolutions more than 3% and 
therefore it would be concluded that the method conditions are 
robust. 
The proposed RP-HPLC method was applied to the simultaneous 
estimation of real samples (Ecosprin® Gold20 Capsules) containing 
ASP, ATV and CLP. Representative chromatograms are presented in 
Fig. 3. The results achieved when analyzing Ecosprin® Gold20 
Capsules was 75 mg of ASP, CLP and 20 mg of ATV, with the values 
within parenthesis being the % CV of the six replicates. Good 
agreement was found between the assay results and the label claim 
of the product. The % CV of Capsules was < 2, indicating the 
precision of the analytical methodology. 
CONCLUSION 
Statistically based experimental designs proved to be a valuable 
approach in optimizing selectivity-controlling parameters for the 
determination of ASP, ATV, and CLP in pharmaceutical dosage form. 
The significant factors were optimized by applying central 
composite design and surface response methodology. The objective 
responses, resolution and the analysis time, were then 
simultaneously optimized by applying Derringer's desirability 
function, a multi-criteria decision making tool. The improved 
method showed higher sensitivity and shorter analysis time than the 
existing method making it viable to be implemented for routine 
quality control analysis in a pharmaceutical laboratory. The method 
validation studies supported the selection of the assay conditions 
was specific, accurate, linear, precise, and robust. 
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